NZ628416A - Treatment of cancer with tor kinase inhibitors - Google Patents

Treatment of cancer with tor kinase inhibitors

Info

Publication number
NZ628416A
NZ628416A NZ628416A NZ62841613A NZ628416A NZ 628416 A NZ628416 A NZ 628416A NZ 628416 A NZ628416 A NZ 628416A NZ 62841613 A NZ62841613 A NZ 62841613A NZ 628416 A NZ628416 A NZ 628416A
Authority
NZ
New Zealand
Prior art keywords
tor kinase
cancer
treatment
kinase inhibitors
cell carcinoma
Prior art date
Application number
NZ628416A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Lilly Loraine Wong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NZ628416A publication Critical patent/NZ628416A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ628416A 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors NZ628416A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ628416A true NZ628416A (en) 2016-04-29

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628416A NZ628416A (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Country Status (21)

Country Link
US (1) US20130245026A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015510891A (cg-RX-API-DMAC7.html)
KR (3) KR102122617B1 (cg-RX-API-DMAC7.html)
CN (2) CN104519885A (cg-RX-API-DMAC7.html)
AU (1) AU2013203153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2866872A1 (cg-RX-API-DMAC7.html)
EA (1) EA028414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2677874T3 (cg-RX-API-DMAC7.html)
IL (1) IL234602B (cg-RX-API-DMAC7.html)
MX (1) MX360878B (cg-RX-API-DMAC7.html)
MY (1) MY174022A (cg-RX-API-DMAC7.html)
NI (1) NI201400111A (cg-RX-API-DMAC7.html)
NZ (1) NZ628416A (cg-RX-API-DMAC7.html)
PH (1) PH12014502029B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405707XA (cg-RX-API-DMAC7.html)
TW (1) TWI583385B (cg-RX-API-DMAC7.html)
UA (1) UA114315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013138557A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406706B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Also Published As

Publication number Publication date
WO2013138557A1 (en) 2013-09-19
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
AU2013203153B2 (en) 2015-09-03
BR112014022703A2 (pt) 2021-05-04
JP2019108368A (ja) 2019-07-04
PH12014502029A1 (en) 2014-11-24
ZA201406706B (en) 2016-05-25
TWI583385B (zh) 2017-05-21
JP2021102637A (ja) 2021-07-15
KR20140138927A (ko) 2014-12-04
EA028414B1 (ru) 2017-11-30
EA201491699A1 (ru) 2015-02-27
CA2866872A1 (en) 2013-09-19
IL234602B (en) 2020-05-31
SG11201405707XA (en) 2014-10-30
HK1201750A1 (en) 2015-09-11
CN104519885A (zh) 2015-04-15
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
JP2015510891A (ja) 2015-04-13
MY174022A (en) 2020-03-04
ES2677874T3 (es) 2018-08-07
KR102122617B1 (ko) 2020-06-12
EP2825170B1 (en) 2018-05-09
KR20210071101A (ko) 2021-06-15
EP2825170A1 (en) 2015-01-21
IL234602A0 (en) 2014-11-30
UA114315C2 (uk) 2017-05-25
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
MX360878B (es) 2018-11-21

Similar Documents

Publication Publication Date Title
NZ628420A (en) Treatment of cancer with tor kinase inhibitors
NZ628421A (en) Treatment of cancer with tor kinase inhibitors
NZ628407A (en) Treatment of cancer with tor kinase inhibitors
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
UA110697C2 (uk) ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
IL281180A (en) 1-Ethyl-7-(2-methyl-6-(4H-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[3,2-b]pyrazine-2 (1H)-one for cancer treatment
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
PT3808749T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
UA117590C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
MX2013010840A (es) Metodos para inhibir c-kit mutante.
MY172308A (en) Bicyclic pyrazinone derivatives
MY164705A (en) Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor
PH12018501137B1 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
IL241950B (en) Compound 1-ethyl-7-(2-methyl-6-(1h-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[2,3-b]pyrazine- 2(1h)-ven for the treatment of glioblastoma multiforme
WO2014038881A3 (ko) 피리돈 유도체를 포함하는 단백질 키나제 억제제
TH165140A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
TH165139A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ717887A (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

LAPS Patent lapsed